首页 > 最新文献

Recent Advances in Inflammation & Allergy Drug Discovery最新文献

英文 中文
Tumor Suppressor microRNAs in Gastrointestinal Cancers: A Mini-Review. 肿瘤抑制microrna在胃肠道肿瘤中的应用综述
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220606112727
Ganesan Jothimani, Meenu Bhatiya, Surajit Pathak, Sujay Paul, Antara Banerjee

Background: Gastrointestinal (GI) cancer is associated with a group of cancers affecting the organs in the GI tract, with a high incidence and mortality rate. This type of cancer development involves a series of molecular events that arise by the dysregulation of gene expressions and microRNAs (miRNAs).

Objectives: This mini-review focuses on elucidating the mechanism of tumor suppressor miRNA-mediated oncogenic gene silencing, which may contribute to a better understanding of miRNA-mediated gene expression regulation of cell cycle, proliferation, invasion, and apoptosis in GI cancers. In this review, the biological significance of tumor suppressor miRNAs involved in gastrointestinal cancers is briefly explained.

Methods: The articles were searched with the keywords 'miRNA', 'gastrointestinal cancers', 'esophageal cancer', 'gastric cancer', 'colorectal cancer', 'pancreatic cancer', 'liver cancer', and 'gall bladder cancer' from the Google Scholar and PubMed databases. A total of 71 research and review articles have been collected and referred for this study.

Results: This review summarises recent research enhancing the effectiveness of miRNAs as novel prognostic, diagnostic, and therapeutic markers for GI cancer treatment strategies. The expression pattern of various miRNAs has been dysregulated in GI cancers, which are associated with proliferation, cell cycle regulation, apoptosis, migration, and invasion.

Conclusion: The role of tumor suppressor miRNAs in the negative regulation of oncogenic gene expression was thoroughly explained in this review. Its potential role as a microRNA therapeutic candidate is also discussed. Profiling and regulating tumor suppressor miRNA expression in gastrointestinal cancers using miRNA mimics could be used as a prognostic, diagnostic, and therapeutic marker, as well as an elucidating molecular therapeutic approach to tumor suppression.

背景:胃肠道(GI)癌是一类影响胃肠道器官的肿瘤,具有较高的发病率和死亡率。这种类型的癌症发展涉及一系列由基因表达和microrna (miRNAs)失调引起的分子事件。目的:本综述旨在阐明肿瘤抑制因子mirna介导的癌基因沉默机制,有助于更好地理解mirna介导的基因表达调控胃肠道肿瘤细胞周期、增殖、侵袭和凋亡。本文就肿瘤抑制mirna在胃肠道肿瘤中的生物学意义作一综述。方法:以关键词“miRNA”、“胃肠道癌”、“食道癌”、“胃癌”、“结直肠癌”、“胰腺癌”、“肝癌”、“胆囊癌”从Google Scholar和PubMed数据库中检索文章。本研究共收集和参考了71篇研究和综述文章。结果:本文综述了最近的研究,这些研究增强了mirna作为胃肠道肿瘤治疗策略的新型预后、诊断和治疗标志物的有效性。多种mirna的表达模式在胃肠道肿瘤中失调,与增殖、细胞周期调节、凋亡、迁移和侵袭有关。结论:本文对肿瘤抑制mirna在肿瘤基因表达负调控中的作用进行了较全面的阐述。它作为一个潜在的microRNA治疗候选者的作用也进行了讨论。利用miRNA模拟物分析和调节胃肠道肿瘤中肿瘤抑制miRNA的表达,可以作为一种预后、诊断和治疗标志物,以及一种阐明肿瘤抑制的分子治疗方法。
{"title":"Tumor Suppressor microRNAs in Gastrointestinal Cancers: A Mini-Review.","authors":"Ganesan Jothimani,&nbsp;Meenu Bhatiya,&nbsp;Surajit Pathak,&nbsp;Sujay Paul,&nbsp;Antara Banerjee","doi":"10.2174/2772270816666220606112727","DOIUrl":"https://doi.org/10.2174/2772270816666220606112727","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) cancer is associated with a group of cancers affecting the organs in the GI tract, with a high incidence and mortality rate. This type of cancer development involves a series of molecular events that arise by the dysregulation of gene expressions and microRNAs (miRNAs).</p><p><strong>Objectives: </strong>This mini-review focuses on elucidating the mechanism of tumor suppressor miRNA-mediated oncogenic gene silencing, which may contribute to a better understanding of miRNA-mediated gene expression regulation of cell cycle, proliferation, invasion, and apoptosis in GI cancers. In this review, the biological significance of tumor suppressor miRNAs involved in gastrointestinal cancers is briefly explained.</p><p><strong>Methods: </strong>The articles were searched with the keywords 'miRNA', 'gastrointestinal cancers', 'esophageal cancer', 'gastric cancer', 'colorectal cancer', 'pancreatic cancer', 'liver cancer', and 'gall bladder cancer' from the Google Scholar and PubMed databases. A total of 71 research and review articles have been collected and referred for this study.</p><p><strong>Results: </strong>This review summarises recent research enhancing the effectiveness of miRNAs as novel prognostic, diagnostic, and therapeutic markers for GI cancer treatment strategies. The expression pattern of various miRNAs has been dysregulated in GI cancers, which are associated with proliferation, cell cycle regulation, apoptosis, migration, and invasion.</p><p><strong>Conclusion: </strong>The role of tumor suppressor miRNAs in the negative regulation of oncogenic gene expression was thoroughly explained in this review. Its potential role as a microRNA therapeutic candidate is also discussed. Profiling and regulating tumor suppressor miRNA expression in gastrointestinal cancers using miRNA mimics could be used as a prognostic, diagnostic, and therapeutic marker, as well as an elucidating molecular therapeutic approach to tumor suppression.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10396527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Platelet Count and IgE Level in Chronic Idiopathic Urticaria: A Case-control Study. 慢性特发性荨麻疹的血小板计数和IgE水平:一项病例对照研究。
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220314154951
Rasoul Nasiri Kalmarzi, Mobin Ahmadiniaz, Pedram Ataee, Erfan Babaei, Behzad Khalafi, Wesam Kooti, Ramyar Rahimi Darehbagh

Background and aim: Chronic Urticaria is an allergic disorder that affects about 0.5 to 5% of the population in different communities. The disease's chronic course and long-term onset impose high economic and psychological costs on communities, adversely affecting individual and social life. Platelets play a role in various pathophysiological processes, including inflammation and immunology. Growing evidence suggests that platelets are actively involved in the pathogenesis of various inflammatory disorders, including inflammatory skin diseases. This study investigated the relationship between platelet and immunoglobulin-E markers and chronic idiopathic urticaria.

Materials and methods: In the present case-control study, for the study population, patients with chronic idiopathic urticaria were referred to the Asthma and Allergy Clinic, and their caregivers were selected as the case and control groups, respectively. In this study, the mean platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and Total IgE values were simultaneously measured in the case and control groups. After taking 5CCs of venous blood, a blood sample was sent to the laboratory for platelet and IgE marker measurements.

Results: 100 patients and 100 healthy persons were evaluated in this study. The mean age in the case group was 34.95, and in the control group was 35.78 years. The results showed that the mean values of PLT, MPV, PDW, and Total IgE in the case group were 12.86, 9.83, 252190, and 147.05, respectively. The mean values of PLT, MPV, PDW, and Total IgE in the control group were 16.93, 7.53, 231410, and 15.29, respectively, which was statistically significant (P = 0.001). Moreover, total IgE in the Autologous Serum Skin Test (ASST) positive group was higher than ASST negative group and was statistically significant (P = 0.001).

Conclusion: The study results indicate the possible role of platelets in urticaria and inflammation. MPV in patients with chronic urticaria was higher than in the control group. The present study showed no significant relationship between the severity of urticaria and platelet markers, but there was a significant relationship between the severity of urticaria and ASST. Moreover, the severity of urticaria was higher in the positive skin test group.

背景和目的:慢性荨麻疹是一种过敏性疾病,影响不同社区约0.5%至5%的人口。该病的慢性病程和长期发病给社区造成高昂的经济和心理代价,对个人和社会生活产生不利影响。血小板在多种病理生理过程中发挥作用,包括炎症和免疫。越来越多的证据表明,血小板积极参与各种炎症性疾病的发病机制,包括炎症性皮肤病。本研究探讨血小板和免疫球蛋白e标志物与慢性特发性荨麻疹的关系。材料与方法:在本病例对照研究中,研究人群中,慢性特发性荨麻疹患者转至哮喘与过敏诊所,其护理人员分别作为病例组和对照组。本研究同时测定病例组和对照组的平均血小板计数(PLT)、平均血小板体积(MPV)、血小板分布宽度(PDW)和总IgE值。取静脉血5cc后,将血样送到实验室进行血小板和IgE标记物测定。结果:本研究对100例患者和100名健康人进行了评价。病例组平均年龄34.95岁,对照组平均年龄35.78岁。结果显示,病例组PLT、MPV、PDW、Total IgE均值分别为12.86、9.83、252190、147.05。对照组患者PLT、MPV、PDW、Total IgE均值分别为16.93、7.53、231410、15.29,差异均有统计学意义(P = 0.001)。自体血清皮肤试验(自体血清皮肤试验)阳性组总IgE高于阴性组,差异有统计学意义(P = 0.001)。结论:本研究结果提示血小板在荨麻疹和炎症中的可能作用。慢性荨麻疹患者的MPV高于对照组。本研究显示,荨麻疹的严重程度与血小板标志物之间没有明显的关系,但荨麻疹的严重程度与asst之间存在显著的关系,并且皮肤试验阳性组的荨麻疹严重程度更高。
{"title":"Platelet Count and IgE Level in Chronic Idiopathic Urticaria: A Case-control Study.","authors":"Rasoul Nasiri Kalmarzi,&nbsp;Mobin Ahmadiniaz,&nbsp;Pedram Ataee,&nbsp;Erfan Babaei,&nbsp;Behzad Khalafi,&nbsp;Wesam Kooti,&nbsp;Ramyar Rahimi Darehbagh","doi":"10.2174/2772270816666220314154951","DOIUrl":"https://doi.org/10.2174/2772270816666220314154951","url":null,"abstract":"<p><strong>Background and aim: </strong>Chronic Urticaria is an allergic disorder that affects about 0.5 to 5% of the population in different communities. The disease's chronic course and long-term onset impose high economic and psychological costs on communities, adversely affecting individual and social life. Platelets play a role in various pathophysiological processes, including inflammation and immunology. Growing evidence suggests that platelets are actively involved in the pathogenesis of various inflammatory disorders, including inflammatory skin diseases. This study investigated the relationship between platelet and immunoglobulin-E markers and chronic idiopathic urticaria.</p><p><strong>Materials and methods: </strong>In the present case-control study, for the study population, patients with chronic idiopathic urticaria were referred to the Asthma and Allergy Clinic, and their caregivers were selected as the case and control groups, respectively. In this study, the mean platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and Total IgE values were simultaneously measured in the case and control groups. After taking 5CCs of venous blood, a blood sample was sent to the laboratory for platelet and IgE marker measurements.</p><p><strong>Results: </strong>100 patients and 100 healthy persons were evaluated in this study. The mean age in the case group was 34.95, and in the control group was 35.78 years. The results showed that the mean values of PLT, MPV, PDW, and Total IgE in the case group were 12.86, 9.83, 252190, and 147.05, respectively. The mean values of PLT, MPV, PDW, and Total IgE in the control group were 16.93, 7.53, 231410, and 15.29, respectively, which was statistically significant (P = 0.001). Moreover, total IgE in the Autologous Serum Skin Test (ASST) positive group was higher than ASST negative group and was statistically significant (P = 0.001).</p><p><strong>Conclusion: </strong>The study results indicate the possible role of platelets in urticaria and inflammation. MPV in patients with chronic urticaria was higher than in the control group. The present study showed no significant relationship between the severity of urticaria and platelet markers, but there was a significant relationship between the severity of urticaria and ASST. Moreover, the severity of urticaria was higher in the positive skin test group.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10335513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural Approach in Osteoarthritis Therapy. 骨关节炎的自然疗法。
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220331163707
Alice Grigore, Virginia Vulturescu

Osteoarthritis (OA) is the most common joint disease worldwide, and its rising prevalence is supported by factors such as obesity and sedentariness. At the molecular level, it is considered an inflammatory disease that leads to the destruction of articular cartilage. Effective therapy to end the degenerative process of arthritis remains elusive, and most therapeutic tools prevent the progress or alleviate the symptoms. By now, medicines for OA are available for oral, topical, or intra-articular (IA) therapy and include analgesics, nonsteroidal anti-inflammatory drugs, corticosteroids, and hyaluronic acid. Compared with conventional oral administration, IA therapy has multiple advantages in terms of bioavailability, efficacy, and toxicity. This review aims to study the underlying beneficial effects of herbal medicine in OA therapy and to open new research perspectives. Herbal medicine administered orally or topically exhibits pharmacological properties that could be relevant for their beneficial effect in OA, mainly anti-inflammatory and antioxidant effects. There are few studies regarding IA injections of plant extracts/ compounds and none related to any combination with agents already used in the clinic. Designing natural pharmaceutical formulations with increased bioavailability that are safe, lack side effects, and are specifically tested, would be a plus for research on medicinal plants and a novelty for the clinic.

骨关节炎(OA)是世界范围内最常见的关节疾病,其发病率的上升与肥胖和久坐等因素有关。在分子水平上,它被认为是一种导致关节软骨破坏的炎症性疾病。有效的治疗方法来结束关节炎的退行性过程仍然是难以捉摸的,大多数治疗工具防止进展或减轻症状。目前,治疗OA的药物可用于口服、局部或关节内(IA)治疗,包括镇痛药、非甾体抗炎药、皮质类固醇和透明质酸。与传统的口服给药相比,IA治疗在生物利用度、疗效和毒性方面具有多重优势。本文旨在研究中药在OA治疗中的潜在有益作用,并开辟新的研究前景。口服或局部使用的草药显示出可能与OA有益作用相关的药理学特性,主要是抗炎和抗氧化作用。关于植物提取物/化合物的IA注射的研究很少,也没有与临床已经使用的药物的任何组合有关。设计具有更高生物利用度的天然药物配方,安全,没有副作用,并经过专门测试,将是药用植物研究的一个加分项,也是临床的一个新奇之处。
{"title":"Natural Approach in Osteoarthritis Therapy.","authors":"Alice Grigore,&nbsp;Virginia Vulturescu","doi":"10.2174/2772270816666220331163707","DOIUrl":"https://doi.org/10.2174/2772270816666220331163707","url":null,"abstract":"<p><p>Osteoarthritis (OA) is the most common joint disease worldwide, and its rising prevalence is supported by factors such as obesity and sedentariness. At the molecular level, it is considered an inflammatory disease that leads to the destruction of articular cartilage. Effective therapy to end the degenerative process of arthritis remains elusive, and most therapeutic tools prevent the progress or alleviate the symptoms. By now, medicines for OA are available for oral, topical, or intra-articular (IA) therapy and include analgesics, nonsteroidal anti-inflammatory drugs, corticosteroids, and hyaluronic acid. Compared with conventional oral administration, IA therapy has multiple advantages in terms of bioavailability, efficacy, and toxicity. This review aims to study the underlying beneficial effects of herbal medicine in OA therapy and to open new research perspectives. Herbal medicine administered orally or topically exhibits pharmacological properties that could be relevant for their beneficial effect in OA, mainly anti-inflammatory and antioxidant effects. There are few studies regarding IA injections of plant extracts/ compounds and none related to any combination with agents already used in the clinic. Designing natural pharmaceutical formulations with increased bioavailability that are safe, lack side effects, and are specifically tested, would be a plus for research on medicinal plants and a novelty for the clinic.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10339944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target. GDF15在血管和肝脏代谢紊乱中的作用:一个新的治疗靶点。
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/277227081602221221113442
Stefano Fiorucci, Ginevra Urbani
{"title":"GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target.","authors":"Stefano Fiorucci,&nbsp;Ginevra Urbani","doi":"10.2174/277227081602221221113442","DOIUrl":"https://doi.org/10.2174/277227081602221221113442","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10634749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Growth Differentiation Factor 15 with Arterial Stiffness and Endothelial Function in Subpopulations of Patients with Coronary Artery Disease: A Proof-of-Concept Study. 冠状动脉疾病患者亚群中生长分化因子15与动脉僵硬和内皮功能的关联:一项概念验证研究
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270817666221104120923
Konstantinos Mourouzis, Gerasimos Siasos, Nikoleta Bozini, Evangelos Oikonomou, Marina Zaromitidou, Vasiliki Tsigkou, Eleni Kokkou, Evanthia Bletsa, Panagiota Stampouloglou, Manolis Vavuranakis, Dimitrios Tousoulis

Background: Growth-differentiation factor-15 (GDF-15) is a biomarker belonging to the transforming growth factor-beta cytokine superfamily, which is linked to many pathological conditions, including inflammation and myocardial injury. Pulse wave velocity (cfPWV) and augmentation index (AIx) are indices of arterial stiffness, which are associated with the severity of coronary artery disease (CAD). Flow-mediated dilatation (FMD) is a well-studied surrogate marker of endothelial-dependent dysfunction and systemic inflammation.

Objective: In this proof-of-concept study, we aimed to investigate the relationship between circulating GDF-15, endothelial dysfunction, and indices of arterial stiffness in different settings of coronary artery disease and myocardial injury.

Methods: In this cross-sectional single-center study, we enrolled patients (n = 22) after interventional treatment for acute myocardial infarction (AMI), patients (n = 11) admitted with chest pain and elevated cardiac enzymes but without evidence of obstructing CAD (MI-NOCAD) in percutaneous coronary angiography (CAG), and patients (n = 20) who underwent CAG according to indications without evident obstructive CAD in CAG (NOCAD). FMD was assessed at the brachial artery. AIx of the central aortic pressure and cfPWV were estimated by applanation tonometry at the radial and carotid-femoral site, respectively, with a validated acquisition system (Sphygmo- Cor, AtCor Medical, Sydney (NSW), Australia). ELISA was used to determine circulating GDF- 15 serum levels (R&D Systems, Minneapolis, MN). Clinical and demographic data and values of routine biochemical biomarkers were obtained. The highest high-sensitive cardiac Troponin I (hsTpnI) value during hospitalization was also recorded. Left ventricular ejection fraction (LVEF) was assessed with a transthoracic echocardiogram.

Results: Patients with AMI were older, had worse LVEF, higher values of hsTpnI and increased circulating GDF-15 levels. Importantly, AMI patients had increased cfPWV values, deteriorated AIx values, blunted FMD and worse serum creatinine levels compared to MI-NOCAD and NOCAD patients, respectively, whereas MI-NOCAD and NOCAD did not differ from each other significantly on these biomarkers. Both AMI and MI-NOCAD patients presented a higher but comparable white blood cell count than NOCAD patients. A strong linear correlation between GDF-15 and cfPWV, hsTpnI, AIx, white blood cell count and creatinine but not with FMD was demonstrated in the general study population.

Conclusion: This proof-of-concept study showed that higher circulating levels of GDF-15, an inflammatory biomarker, were associated significantly with increased arterial stiffness only in AMI patients, whereas elevated GDF-15 demonstrated a linear relationship with the severity of the myocardial injury.

背景:生长分化因子-15 (growth -differentiation factor-15, GDF-15)是一种生物标志物,属于转化生长因子-细胞因子超家族,与许多病理状况有关,包括炎症和心肌损伤。脉搏波速度(cfPWV)和增强指数(AIx)是动脉硬度的指标,与冠状动脉疾病(CAD)的严重程度相关。血流介导的扩张(FMD)是内皮依赖性功能障碍和全身性炎症的一个被充分研究的替代标志物。目的:在这项概念验证性研究中,我们旨在探讨不同冠状动脉疾病和心肌损伤情况下循环GDF-15、内皮功能障碍和动脉僵硬指数之间的关系。方法:在这项横断面单中心研究中,我们招募了22例急性心肌梗死(AMI)介入治疗后的患者,11例胸痛和心肌酶升高但经皮冠状动脉造影(CAG)无阻塞性CAD (MI-NOCAD)证据的患者,以及20例根据适应症行CAG的患者,CAG中无明显阻塞性CAD (NOCAD)证据。在肱动脉处评估FMD。采用经过验证的采集系统(Sphygmo- Cor, AtCor Medical, Sydney (NSW), Australia),分别通过桡动脉和颈动脉-股动脉部位的压平血压计估计中央主动脉压的AIx和cfPWV。ELISA检测血清循环GDF- 15水平(R&D Systems, Minneapolis, MN)。获得临床和人口统计学资料及常规生化生物标志物值。同时记录住院期间高敏感心肌肌钙蛋白I (hsTpnI)值的最高值。左心室射血分数(LVEF)经胸超声心动图评估。结果:AMI患者年龄较大,LVEF较差,hsTpnI值较高,循环GDF-15水平升高。重要的是,与MI-NOCAD和NOCAD患者相比,AMI患者的cfPWV值升高,AIx值变差,FMD变钝,血清肌酐水平变差,而MI-NOCAD和NOCAD在这些生物标志物上没有显著差异。AMI和MI-NOCAD患者的白细胞计数均高于NOCAD患者。在一般研究人群中,GDF-15与cfPWV、hsTpnI、AIx、白细胞计数和肌酐之间存在很强的线性相关性,但与口蹄疫无关。结论:这项概念验证性研究表明,较高的循环GDF-15水平(一种炎症生物标志物)仅在AMI患者中与动脉僵硬度增加显著相关,而升高的GDF-15与心肌损伤的严重程度呈线性关系。
{"title":"Association of Growth Differentiation Factor 15 with Arterial Stiffness and Endothelial Function in Subpopulations of Patients with Coronary Artery Disease: A Proof-of-Concept Study.","authors":"Konstantinos Mourouzis,&nbsp;Gerasimos Siasos,&nbsp;Nikoleta Bozini,&nbsp;Evangelos Oikonomou,&nbsp;Marina Zaromitidou,&nbsp;Vasiliki Tsigkou,&nbsp;Eleni Kokkou,&nbsp;Evanthia Bletsa,&nbsp;Panagiota Stampouloglou,&nbsp;Manolis Vavuranakis,&nbsp;Dimitrios Tousoulis","doi":"10.2174/2772270817666221104120923","DOIUrl":"https://doi.org/10.2174/2772270817666221104120923","url":null,"abstract":"<p><strong>Background: </strong>Growth-differentiation factor-15 (GDF-15) is a biomarker belonging to the transforming growth factor-beta cytokine superfamily, which is linked to many pathological conditions, including inflammation and myocardial injury. Pulse wave velocity (cfPWV) and augmentation index (AIx) are indices of arterial stiffness, which are associated with the severity of coronary artery disease (CAD). Flow-mediated dilatation (FMD) is a well-studied surrogate marker of endothelial-dependent dysfunction and systemic inflammation.</p><p><strong>Objective: </strong>In this proof-of-concept study, we aimed to investigate the relationship between circulating GDF-15, endothelial dysfunction, and indices of arterial stiffness in different settings of coronary artery disease and myocardial injury.</p><p><strong>Methods: </strong>In this cross-sectional single-center study, we enrolled patients (n = 22) after interventional treatment for acute myocardial infarction (AMI), patients (n = 11) admitted with chest pain and elevated cardiac enzymes but without evidence of obstructing CAD (MI-NOCAD) in percutaneous coronary angiography (CAG), and patients (n = 20) who underwent CAG according to indications without evident obstructive CAD in CAG (NOCAD). FMD was assessed at the brachial artery. AIx of the central aortic pressure and cfPWV were estimated by applanation tonometry at the radial and carotid-femoral site, respectively, with a validated acquisition system (Sphygmo- Cor, AtCor Medical, Sydney (NSW), Australia). ELISA was used to determine circulating GDF- 15 serum levels (R&D Systems, Minneapolis, MN). Clinical and demographic data and values of routine biochemical biomarkers were obtained. The highest high-sensitive cardiac Troponin I (hsTpnI) value during hospitalization was also recorded. Left ventricular ejection fraction (LVEF) was assessed with a transthoracic echocardiogram.</p><p><strong>Results: </strong>Patients with AMI were older, had worse LVEF, higher values of hsTpnI and increased circulating GDF-15 levels. Importantly, AMI patients had increased cfPWV values, deteriorated AIx values, blunted FMD and worse serum creatinine levels compared to MI-NOCAD and NOCAD patients, respectively, whereas MI-NOCAD and NOCAD did not differ from each other significantly on these biomarkers. Both AMI and MI-NOCAD patients presented a higher but comparable white blood cell count than NOCAD patients. A strong linear correlation between GDF-15 and cfPWV, hsTpnI, AIx, white blood cell count and creatinine but not with FMD was demonstrated in the general study population.</p><p><strong>Conclusion: </strong>This proof-of-concept study showed that higher circulating levels of GDF-15, an inflammatory biomarker, were associated significantly with increased arterial stiffness only in AMI patients, whereas elevated GDF-15 demonstrated a linear relationship with the severity of the myocardial injury.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10754885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased ACE2, sRAGE, and Immune Activation, but Lowered Calcium and Magnesium in COVID-19. 在COVID-19中,ACE2、sRAGE和免疫激活增加,但钙和镁降低。
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220318103929
Hussein Kadhem Al-Hakeim, Hawraa Kadhem Al-Jassas, Gerwyn Morris, Michael Maes

Background: The characterization of new biomarkers that could help externally validate the diagnosis of COVID-19 and optimize treatments is extremely important. Many studies have established changes in immune-inflammatory and antibody levels, but few studies measured the soluble receptor for the advanced glycation end product (sRAGE), angiotensin-converting enzyme 2 (ACE2), calcium, and magnesium in COVID-19.

Objective: To evaluate serum advanced glycation end-product receptor (sRAGE) and angiotensin converting enzyme (ACE)2 and peripheral oxygen saturation (SpO2) and chest CT scan abnormalities (CCTA) in COVID-19.

Methods: sRAGE, ACE2, interleukin (IL)-6, IL-10, C-reactive protein (CRP), calcium, magnesium, and albumin were measured in 60 COVID-19 patients and 30 healthy controls.

Results: COVID-19 is characterized by significantly increased IL-6, CRP, IL-10, sRAGE, ACE2, and lowered SpO2, albumin, magnesium, and calcium. COVID-19 with CCTAs showed lower SpO2 and albumin. SpO2 was significantly inversely correlated with IL-6, IL-10, CRP, sRAGE, and ACE2, and positively with albumin, magnesium, and calcium. Neural networks showed that a combination of calcium, IL-6, CRP, and sRAGE yielded an accuracy of 100% in detecting COVID-19 patients, with calcium being the most important predictor followed by IL-6 and CRP. Patients with positive IgG results showed a significant elevation in the serum level of IL-6, sRAGE, and ACE2 compared to the negatively IgG patient subgroup.

Conclusion: The results show that immune-inflammatory and RAGE pathways biomarkers may be used as an external validating criterion for the diagnosis of COVID-19. Those pathways coupled with lowered SpO2, calcium, and magnesium are drug targets that may help reduce the consequences of COVID-19.

背景:鉴定新的生物标志物,以帮助外部验证COVID-19的诊断和优化治疗是非常重要的。许多研究已经确定了免疫炎症和抗体水平的变化,但很少有研究测量了COVID-19中晚期糖基化终产物(sRAGE)、血管紧张素转换酶2 (ACE2)、钙和镁的可溶性受体。目的:评价COVID-19患者血清晚期糖基化终产物受体(sRAGE)、血管紧张素转换酶(ACE)2、外周血氧饱和度(SpO2)及胸部CT扫描异常(CCTA)。方法:测定60例COVID-19患者和30例健康对照者的sRAGE、ACE2、白细胞介素(IL)-6、IL-10、c反应蛋白(CRP)、钙、镁、白蛋白含量。结果:COVID-19的特点是IL-6、CRP、IL-10、sRAGE、ACE2显著升高,SpO2、白蛋白、镁、钙显著降低。ccta组的COVID-19表现为SpO2和白蛋白较低。SpO2与IL-6、IL-10、CRP、sRAGE、ACE2呈显著负相关,与白蛋白、镁、钙呈显著正相关。神经网络显示,钙、IL-6、CRP和sRAGE联合检测COVID-19患者的准确率为100%,其中钙是最重要的预测因子,其次是IL-6和CRP。与IgG阴性患者亚组相比,IgG阳性患者血清IL-6、sRAGE和ACE2水平显著升高。结论:免疫炎症和RAGE通路生物标志物可作为COVID-19诊断的外部验证标准。这些途径加上SpO2、钙和镁的降低,是可能有助于减少COVID-19后果的药物靶点。
{"title":"Increased ACE2, sRAGE, and Immune Activation, but Lowered Calcium and Magnesium in COVID-19.","authors":"Hussein Kadhem Al-Hakeim,&nbsp;Hawraa Kadhem Al-Jassas,&nbsp;Gerwyn Morris,&nbsp;Michael Maes","doi":"10.2174/2772270816666220318103929","DOIUrl":"https://doi.org/10.2174/2772270816666220318103929","url":null,"abstract":"<p><strong>Background: </strong>The characterization of new biomarkers that could help externally validate the diagnosis of COVID-19 and optimize treatments is extremely important. Many studies have established changes in immune-inflammatory and antibody levels, but few studies measured the soluble receptor for the advanced glycation end product (sRAGE), angiotensin-converting enzyme 2 (ACE2), calcium, and magnesium in COVID-19.</p><p><strong>Objective: </strong>To evaluate serum advanced glycation end-product receptor (sRAGE) and angiotensin converting enzyme (ACE)2 and peripheral oxygen saturation (SpO2) and chest CT scan abnormalities (CCTA) in COVID-19.</p><p><strong>Methods: </strong>sRAGE, ACE2, interleukin (IL)-6, IL-10, C-reactive protein (CRP), calcium, magnesium, and albumin were measured in 60 COVID-19 patients and 30 healthy controls.</p><p><strong>Results: </strong>COVID-19 is characterized by significantly increased IL-6, CRP, IL-10, sRAGE, ACE2, and lowered SpO2, albumin, magnesium, and calcium. COVID-19 with CCTAs showed lower SpO<sub>2</sub> and albumin. SpO2 was significantly inversely correlated with IL-6, IL-10, CRP, sRAGE, and ACE2, and positively with albumin, magnesium, and calcium. Neural networks showed that a combination of calcium, IL-6, CRP, and sRAGE yielded an accuracy of 100% in detecting COVID-19 patients, with calcium being the most important predictor followed by IL-6 and CRP. Patients with positive IgG results showed a significant elevation in the serum level of IL-6, sRAGE, and ACE2 compared to the negatively IgG patient subgroup.</p><p><strong>Conclusion: </strong>The results show that immune-inflammatory and RAGE pathways biomarkers may be used as an external validating criterion for the diagnosis of COVID-19. Those pathways coupled with lowered SpO2, calcium, and magnesium are drug targets that may help reduce the consequences of COVID-19.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10450949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Role of mRAGEs and ACE2 in SARS-CoV-2-Related Inflammation. mRAGEs和ACE2在sars - cov -2相关炎症中的作用
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/277227081601221018140453
Stefano Fiorucci, Ginevra Urbani
{"title":"Role of mRAGEs and ACE2 in SARS-CoV-2-Related Inflammation.","authors":"Stefano Fiorucci,&nbsp;Ginevra Urbani","doi":"10.2174/277227081601221018140453","DOIUrl":"https://doi.org/10.2174/277227081601221018140453","url":null,"abstract":"","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10403346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under In Vitro Examination on L929 and Hepatocellular Carcinoma Cell Lines. α- l -古鲁醛酸(G2013)作为一种新型非甾体抗炎药对L929和肝癌细胞系的安全性、特性和凋亡作用的体外研究
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772434416666210909111912
Shahrzad Hassani, Jalil Tavakol Afshari, Fahimeh Jafarnezhad-Ansariha, Abbas Mirshafiey

Background: Many investigations have expanded this concept that liver chronic inflammation has an essential role in persistent cell damages along with altering the liver microenvironment leading to fibrosis, cirrhosis, and finally, hepatocellular carcinoma (HCC). To reduce inflammation and relieve symptoms, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly used; however, their long-term usage can lead to severe adverse events on vital organs like the liver. Interestingly, the α-L-Guluronic Acid (G2013), as a novel NSAID with immunomodulatory properties, has shown the inhibitory effects on inflammation and metastasis in experimental models.

Objective: This study was conducted to determine the effects of G2013 on cytotoxicity and induction of apoptosis, as a new therapeutic target for cancer therapy, in the HepG2 cell line and the mouse fibroblast cell line L929, as a control.

Methods: MTT assay and flow cytometry method were carried out using the different concentrations of G2013 (5, 15, 25, 50, 100, 200 and 400 μg/ml) in 3 distinct incubation times.

Results: Our data showed that treatment of HepG2 cells with high concentration (400μg/mL) of G2013 could effectively cause a decrease in cell viability, so that they were statistically different after 72 hours compared to other concentrations (5 to 200 μg/ml) (p<0.05 and p<0.01, respectively). Moreover, the proportion of apoptosis of HepG2 cells at the dose of 200μg/mL considerably increased, suggesting that the induction of apoptosis by G2013 in HepG2 cells is dose- and time-dependent, which could promote its anticancer properties.

Conclusion: The present study revealed that G2013 could induce apoptosis in the liver cancer model. Therefore, based on these findings, G2013 might be considered as a therapeutic option in cancer therapy.

背景:许多研究已经扩展了这一概念,即肝脏慢性炎症在持续细胞损伤中起重要作用,并改变肝脏微环境,导致纤维化、肝硬化,最终导致肝细胞癌(HCC)。为了减轻炎症和缓解症状,通常使用非甾体抗炎药(NSAIDs);然而,它们的长期使用会导致肝脏等重要器官发生严重的不良事件。有趣的是,α- l -古鲁醛酸(G2013)作为一种具有免疫调节特性的新型非甾体抗炎药,在实验模型中显示出对炎症和转移的抑制作用。目的:本研究以HepG2细胞系和小鼠成纤维细胞系L929为对照,研究G2013作为肿瘤治疗新靶点对细胞毒性和诱导凋亡的影响。方法:采用不同浓度G2013(5、15、25、50、100、200、400 μg/ml)、3个不同孵育时间的MTT法和流式细胞术。结果:我们的数据显示,高浓度(400μg/mL) G2013处理HepG2细胞可有效降低细胞活力,72h后与其他浓度(5 ~ 200 μg/mL)相比有统计学差异(p结论:本研究揭示G2013可诱导肝癌模型细胞凋亡。因此,基于这些发现,G2013可能被认为是癌症治疗的一种治疗选择。
{"title":"The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under <i>In Vitro</i> Examination on L929 and Hepatocellular Carcinoma Cell Lines.","authors":"Shahrzad Hassani,&nbsp;Jalil Tavakol Afshari,&nbsp;Fahimeh Jafarnezhad-Ansariha,&nbsp;Abbas Mirshafiey","doi":"10.2174/2772434416666210909111912","DOIUrl":"https://doi.org/10.2174/2772434416666210909111912","url":null,"abstract":"<p><strong>Background: </strong>Many investigations have expanded this concept that liver chronic inflammation has an essential role in persistent cell damages along with altering the liver microenvironment leading to fibrosis, cirrhosis, and finally, hepatocellular carcinoma (HCC). To reduce inflammation and relieve symptoms, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly used; however, their long-term usage can lead to severe adverse events on vital organs like the liver. Interestingly, the α-L-Guluronic Acid (G2013), as a novel NSAID with immunomodulatory properties, has shown the inhibitory effects on inflammation and metastasis in experimental models.</p><p><strong>Objective: </strong>This study was conducted to determine the effects of G2013 on cytotoxicity and induction of apoptosis, as a new therapeutic target for cancer therapy, in the HepG2 cell line and the mouse fibroblast cell line L929, as a control.</p><p><strong>Methods: </strong>MTT assay and flow cytometry method were carried out using the different concentrations of G2013 (5, 15, 25, 50, 100, 200 and 400 μg/ml) in 3 distinct incubation times.</p><p><strong>Results: </strong>Our data showed that treatment of HepG2 cells with high concentration (400μg/mL) of G2013 could effectively cause a decrease in cell viability, so that they were statistically different after 72 hours compared to other concentrations (5 to 200 μg/ml) (p<0.05 and p<0.01, respectively). Moreover, the proportion of apoptosis of HepG2 cells at the dose of 200μg/mL considerably increased, suggesting that the induction of apoptosis by G2013 in HepG2 cells is dose- and time-dependent, which could promote its anticancer properties.</p><p><strong>Conclusion: </strong>The present study revealed that G2013 could induce apoptosis in the liver cancer model. Therefore, based on these findings, G2013 might be considered as a therapeutic option in cancer therapy.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39402456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Linezolid Intoxication with Extreme Lactate Blood Levels Successfully Treated with Dialytic Treatment in ICU: A Case Report. 重症监护病房透析治疗利奈唑胺中毒并乳酸血症1例。
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220606111049
Lorenzo Schiavoni, Alessia Mattei, Giuseppe Pascarella, Alessandro Strumia, Antonio Nenna, Massimo Chello, Felice E Agrò

Introduction: Lactic acidosis is a rare but life-threatening complication associated with prolonged linezolid therapy. No specific treatment is suggested, except for antibiotic therapy interruption.

Case report: A 70-years-old woman faced severe linezolid intoxication after antibiotics therapy initiation for infection of a surgical sternal wound. The patient suffered from a severe increment of blood lactate and thrombocytopenia. She was admitted to ICU twice, and due to dialytic treatment, linezolid and lactate serum levels came back to normality.

Conclusion: More studies should be conducted to evaluate the human tissue storage sites of linezolid and the influence of various factors on its clearance and plasma concentrations in critically ill patients.

乳酸性酸中毒是一种罕见但危及生命的并发症,与长期利奈唑胺治疗相关。除中断抗生素治疗外,不建议特殊治疗。病例报告:一个70岁的妇女面临严重的利奈唑胺中毒抗生素治疗开始后,外科胸骨伤口感染。患者出现严重的血乳酸增高和血小板减少症。患者两次入住ICU,经透析治疗,血清利奈唑胺和乳酸水平恢复正常。结论:利奈唑胺在危重患者的人体组织储存部位及各种因素对其清除率和血药浓度的影响有待进一步研究。
{"title":"Linezolid Intoxication with Extreme Lactate Blood Levels Successfully Treated with Dialytic Treatment in ICU: A Case Report.","authors":"Lorenzo Schiavoni,&nbsp;Alessia Mattei,&nbsp;Giuseppe Pascarella,&nbsp;Alessandro Strumia,&nbsp;Antonio Nenna,&nbsp;Massimo Chello,&nbsp;Felice E Agrò","doi":"10.2174/2772270816666220606111049","DOIUrl":"https://doi.org/10.2174/2772270816666220606111049","url":null,"abstract":"<p><strong>Introduction: </strong>Lactic acidosis is a rare but life-threatening complication associated with prolonged linezolid therapy. No specific treatment is suggested, except for antibiotic therapy interruption.</p><p><strong>Case report: </strong>A 70-years-old woman faced severe linezolid intoxication after antibiotics therapy initiation for infection of a surgical sternal wound. The patient suffered from a severe increment of blood lactate and thrombocytopenia. She was admitted to ICU twice, and due to dialytic treatment, linezolid and lactate serum levels came back to normality.</p><p><strong>Conclusion: </strong>More studies should be conducted to evaluate the human tissue storage sites of linezolid and the influence of various factors on its clearance and plasma concentrations in critically ill patients.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10684725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Major Histocompatibility Complex Class II HLA-DRB1 Allelic Epitopes in Fibromyalgia. 纤维肌痛的主要组织相容性复合体II类HLA-DRB1等位基因表位。
IF 0.4 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220321162802
Basant K Puri, Gary S Lee, Armin Schwarzbach

Background: Preliminary evidence has pointed an association of the gene HLA-DRB1 with fibromyalgia. HLA-DRB1 alleles carrying the shared or susceptibility epitope encoding the five-amino acid motif QKRAA, QRRAA or RRRAA in positions 70 to 74 of the major histocompatibility complex class II DRβ chain are associated with several autoimmune diseases.

Objective: The objective of this study was to test the hypothesis that susceptibility epitope-encoding HLA-DRB1 alleles are associated with fibromyalgia.

Methods: Using a case-control design, the prevalence of susceptibility epitope-encoding HLADRB1 alleles in 27 white Caucasian patients fulfilling the revised diagnostic criteria for fibromyalgia of the American College of Rheumatology was compared with that in 27 white Caucasian ageand sex-matched healthy controls.

Results: 13 (48%) of the fibromyalgia patients had susceptibility epitope-coding HLA-DRB1 alleles compared with 15 (56%) of the controls (P = 0.785). The DRB1*01 allele encoding the protective epitope 70-DERAA-74 motif was found in one of the control subjects; none of the fibromyalgia patients had such a protective epitope.

Conclusion: While the present study does not provide evidence supporting the potential role of HLA-DRB1 in the etiology of fibromyalgia, it does not exclude the possibility that there is a polygenic component to a putative genetic causative role.

背景:初步证据表明HLA-DRB1基因与纤维肌痛有关。HLA-DRB1等位基因携带编码主要组织相容性复合体II类DRβ链第70至74位的5个氨基酸基序QKRAA、QRRAA或RRRAA的共享或易感表位,与多种自身免疫性疾病相关。目的:本研究的目的是验证易感性表位编码HLA-DRB1等位基因与纤维肌痛相关的假设。方法:采用病例对照设计,比较27例符合美国风湿病学会修订的纤维肌痛诊断标准的白种人患者与27例年龄和性别匹配的白种人健康对照者的易感表位编码HLADRB1等位基因的患病率。结果:纤维肌痛患者中13例(48%)存在易感表位编码HLA-DRB1等位基因,对照组中15例(56%)存在易感表位编码等位基因(P = 0.785)。在1例对照组中发现编码保护性表位70-DERAA-74基序的DRB1*01等位基因;没有纤维肌痛患者有这样的保护性表位。结论:虽然目前的研究没有提供证据支持HLA-DRB1在纤维肌痛病因学中的潜在作用,但它不排除存在多基因成分的可能性。
{"title":"Major Histocompatibility Complex Class II <i>HLA-DRB1</i> Allelic Epitopes in Fibromyalgia.","authors":"Basant K Puri,&nbsp;Gary S Lee,&nbsp;Armin Schwarzbach","doi":"10.2174/2772270816666220321162802","DOIUrl":"https://doi.org/10.2174/2772270816666220321162802","url":null,"abstract":"<p><strong>Background: </strong>Preliminary evidence has pointed an association of the gene HLA-DRB1 with fibromyalgia. HLA-DRB1 alleles carrying the shared or susceptibility epitope encoding the five-amino acid motif QKRAA, QRRAA or RRRAA in positions 70 to 74 of the major histocompatibility complex class II DRβ chain are associated with several autoimmune diseases.</p><p><strong>Objective: </strong>The objective of this study was to test the hypothesis that susceptibility epitope-encoding HLA-DRB1 alleles are associated with fibromyalgia.</p><p><strong>Methods: </strong>Using a case-control design, the prevalence of susceptibility epitope-encoding HLADRB1 alleles in 27 white Caucasian patients fulfilling the revised diagnostic criteria for fibromyalgia of the American College of Rheumatology was compared with that in 27 white Caucasian ageand sex-matched healthy controls.</p><p><strong>Results: </strong>13 (48%) of the fibromyalgia patients had susceptibility epitope-coding HLA-DRB1 alleles compared with 15 (56%) of the controls (P = 0.785). The DRB1*01 allele encoding the protective epitope 70-DERAA-74 motif was found in one of the control subjects; none of the fibromyalgia patients had such a protective epitope.</p><p><strong>Conclusion: </strong>While the present study does not provide evidence supporting the potential role of HLA-DRB1 in the etiology of fibromyalgia, it does not exclude the possibility that there is a polygenic component to a putative genetic causative role.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10817001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recent Advances in Inflammation & Allergy Drug Discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1